Page Nav

HIDE

Grid Style

GRID_STYLE

Post/Page

Weather Location

Breaking News:

latest

How can countries procure Corona vaccine

No vaccine of the corona virus may have been approved yet, but developed countries have begun taking doses of potential candidates.  More than one billion doses have been traded so far.  This has increased the concern of poor co…





No vaccine of the corona virus may have been approved yet, but developed countries have begun taking doses of potential candidates.  More than one billion doses have been traded so far.  This has increased the concern of poor countries.  International groups and many countries are promising that the vaccine is cheap and available to all, but there will be great difficulty in meeting the demand of 7.8 billion population of the world.  There is growing fear that rich countries will again seize the vaccine supply, as it did in 2009 when the swine flu pandemic spread.  Only the United States, Britain, European Union and Japan have done deals worth 1.3 billion.  If additional supplies and other deals are also completed, about 1.5 billion doses and reserves will be created.  In such a situation, where will the vaccine doses for the rest of the countries come from?

In June, AstraZeneca agreed to give 300 million doses to Gavi's program.  Pfizer and BioNTech have shown interest in supplying doses to Kovacs.  The US government has signed a $ 100 billion deal with Sanofi and Glaxo for $ 2.1 billion.  The US will also have the option of taking 500 million additional doses in the long term.  The European Union is also in the process of bargaining 300 million doses from these two companies.  The US has also signed $ 1.95 billion deal with Pfizer and BioNTech.  A $ 1.6 billion deal has also been signed with Novavax.  A $ 1.2 billion deal has already been signed between AstraZeneca and the US government.  Many rich countries including the United Kingdom, Spain, Israel have made deals with vaccine manufacturers.

Currently, millions of doses have been reserved for the candidates of Moderna, including Oxford University-AstraZeneca and pfizer-biontech se, ahead of the vaccine race.  All of them are going through the final stage trials.  However, the vaccine developers still face many challenges.  First of all, it has to be proved that the vaccine is effective, then approval will have to be taken and manufacturing will have to be increased.  According to AirInfinity, 1 billion doses of global supplies may not be in place before the first quarter of 2022.

No comments